Lilly Will Conduct Additional Xigris Trial For EMEA
This article was originally published in The Pink Sheet Daily
Executive Summary
New trial for European regulators to focus on early identification of sepsis patients and clarifying the drug’s risk/benefit profile.
You may also be interested in...
Xigris Withdrawal’s Impact On Lilly Is Minimal, But Leaves BioCritica Pondering Its Future
Key business questions linger following Eli Lilly & Co.’s announcement on Oct. 25 that it is withdrawing its troubled sepsis drug Xigris from all markets: What’s the impact of the action on Lilly, and what’s next for BioCritica Inc., the start-up formed largely to take over the drug’s commercialization?
Xigris Withdrawal’s Impact On Lilly Is Minimal, But Leaves BioCritica Pondering Its Future
Key business questions linger following Eli Lilly & Co.’s announcement on Oct. 25 that it is withdrawing its troubled sepsis drug Xigris from all markets: What’s the impact of the action on Lilly, and what’s next for BioCritica Inc., the start-up formed largely to take over the drug’s commercialization?
Lilly Xigris Trial Will Use Biomarker To Tailor Treatment
Partner Biosite will develop a rapid protein C diagnostic to be used in the Phase IIb trial, which is set to begin in the fourth quarter of 2006.